 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Duoc-01 / Duke University Medical Center
Trial completion date, Trial primary completion date: DUOC-01: UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells (clinicaltrials.gov) - Sep 28, 2023
P1, N=40, Recruiting, Sponsor: Joanne Kurtzberg, MD
Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- | Duoc-01 / Duke University Medical Center
Journal: Cellular therapies: yesterday, today, and tomorrow. (Pubmed Central) - Apr 5, 2023
Indeed, different types of stem cells (e.g., hematopoietic, mesenchymal, neural, and pluripotent), as well as different lymphoid and myeloid cell populations (e.g., TILs, CAR-Ts, CAR-NKs, and DUOC-01) are being used in clinical settings or are being tested in clinical trials...Technical, ethical, and economic issues persist and they need to be addressed. Undoubtedly, exciting times of challenges and opportunities are coming ahead in the CT arena.
- | Duoc-01 / Duke University Medical Center
Enrollment change, Trial completion date, Trial primary completion date: DUOC-01: UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells (clinicaltrials.gov) - Oct 26, 2022
P1, N=40, Recruiting, Sponsor: Joanne Kurtzberg, MD
Undoubtedly, exciting times of challenges and opportunities are coming ahead in the CT arena. N=12 --> 40 | Trial completion date: Sep 2022 --> Oct 2023 | Trial primary completion date: Sep 2022 --> Oct 2023
- | Duoc-01 / Duke University Medical Center
Enrollment open, Trial initiation date: DUOC for MS: Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 7, 2022
P1, N=20, Recruiting, Sponsor: Joanne Kurtzberg, MD
N=12 --> 40 | Trial completion date: Sep 2022 --> Oct 2023 | Trial primary completion date: Sep 2022 --> Oct 2023 Not yet recruiting --> Recruiting | Initiation date: Nov 2021 --> Jan 2021
- | Duoc-01 / Duke University Medical Center
New P1 trial: DUOC for MS: Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jun 29, 2021
P1, N=20, Not yet recruiting, Sponsor: Joanne Kurtzberg, MD
- | Duoc-01 / Duke University Medical Center
Trial completion date, Trial primary completion date: DUOC-01: UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells (clinicaltrials.gov) - Jun 7, 2019
P1, N=12, Recruiting, Sponsor: Joanne Kurtzberg, MD
Not yet recruiting --> Recruiting | Initiation date: Nov 2021 --> Jan 2021 Trial completion date: Sep 2020 --> Sep 2022 | Trial primary completion date: Sep 2020 --> Sep 2022
- | Duoc-01 / Duke University Medical Center
Trial completion date, Trial primary completion date: DUOC-01: UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells (clinicaltrials.gov) - Jul 24, 2018
P1, N=12, Recruiting, Sponsor: Joanne Kurtzberg, MD
Trial completion date: Sep 2020 --> Sep 2022 | Trial primary completion date: Sep 2020 --> Sep 2022 Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2020
- | Duoc-01 / Duke University Medical Center
Trial primary completion date: DUOC-01: UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells (clinicaltrials.gov) - Apr 4, 2017
P1, N=12, Recruiting, Sponsor: Joanne Kurtzberg, MD
Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2020 Trial primary completion date: Sep 2017 --> Sep 2018
- Duoc-01 / Duke University Medical Center
Enrollment open: DUOC-01: UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells (clinicaltrials.gov) - Oct 10, 2014
P1, N=12, Recruiting, Sponsor: Joanne Kurtzberg, MD
Trial primary completion date: Sep 2017 --> Sep 2018 Not yet recruiting --> Recruiting
- | Duoc-01 / Duke University Medical Center
New P1 trial: DUOC-01: UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells (clinicaltrials.gov) - Oct 2, 2014
P1, N=12, Not yet recruiting, Sponsor: Duke University